Sarepta Therapeutics Inc New (SRPT) Actualités

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

– Applications for the 2025-2026 academic year will be accepted until May 30, 2025 – Scholarships will be awarded to up to 20 individuals living...

Form 8-K - Current report

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

– Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

– Provides non-dilutive financing flexibility and supplements strong balance sheet Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...

Form 4 - Statement of changes in beneficial ownership of securities